Makhoul et al. showed that ANGPT1 rs2445365 was linked to a pathologic complete response (pCR) in their prospective phase II study of the use of bevacizumab as neoadjuvant to chemotherapy in breast cancer patients [24]. The gene discussed is ANGPT1; the disease is breast carcinoma.